UCB S.A.

UCB S.A.

UCBJF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$62.34B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
UCB S.A.UCB S.A.25.70.49%30%40.3
$248.66

Current Fair Value

21.9% downside

Overvalued by 21.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$62.34 Billion
Enterprise Value$65.16 Billion
Annual dividend$1.70
Dividend yield0.49%
Earnings per Share$8.2
Beta0.2
Outstanding Shares190,597,757

Return

Return on Equity30.39%ROE
Return on Assets17.16%
Return on Invested Capital27.48%

Valuation & Multiples

P/E Ratio25.67P/E Ratio
PEG18.53PEG
Price to Sales3.98Price to Sales
Price to Book Ratio5.22Price to Book Ratio
Enterprise Value to Revenue4.22
Enterprise Value to EBIT14.74
Enterprise Value to Net Income18
Total Debt to Enterprise0.06
Debt to Equity0.31Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
July 30, 2026
EPS
$7.81
Est. $5.81
Revenue
$4.88 B
Est. $4.64 B

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
$7.77
Consensus analyst estimate
Revenue Estimate
$5.42 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About UCB S.A.

9,000 employees
CEO: Jean-Christophe Tellier

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized p...

Questions & Answers